Skip to main content

Abstract

It is important to determine if a patient is RhD positive or negative for the purposes of transfusion and pregnancy. Occasionally, the RhD type is not able to be resulted or the result differs from results obtained in the past due to underlying genetic variation in the RHD gene. In these cases, it is important to do further testing using genotype testing to determine if the woman should be managed as RhD positive or RhD negative. If a woman of child-bearing potential makes anti-D antibody, her future pregnancies are at risk of hemolytic disease of the fetus and newborn (HDFN) if a fetus is RhD positive. RhIg is used to protect RhD negative women from this HDFN due to anti-D sensitization. These critical decisions are informed by clarifying the RhD type.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Westhoff CM. The structure and function of the Rh antigen complex. Semin Hematol. 2007;44:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion. 2005;45:1554.

    Article  CAS  PubMed  Google Scholar 

  3. Haspel RL, Westhoff CM. How do I manage Rh typing in obstetric patients? Transfusion. 2015;55:470–4.

    Article  PubMed  Google Scholar 

  4. Sandler SG, Roseff SD, Domen RE, Shaz B, Gottschall JL. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the comprehensive transfusion medicine survey of the College of American Pathologists. Arch Pathol Lab Med. 2014;138:620–5.

    Article  PubMed  Google Scholar 

  5. Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion. 2015;55:680–9.

    Article  CAS  PubMed  Google Scholar 

  6. Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion. 2015;55:2095–103.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Yazer MH, Brunker PA, Bakdash S, et al. Low incidence of D alloimmunization among patients with a serologic weak D phenotype after D+ transfusion. Transfusion. 2016;56:2502–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meghan Delaney D.O., M.P.H. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Delaney, M. (2018). Weak D in Pregnancy. In: Nester, T. (eds) Transfusion Management of the Obstetrical Patient. Springer, Cham. https://doi.org/10.1007/978-3-319-77140-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-77140-3_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-77139-7

  • Online ISBN: 978-3-319-77140-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics